Lexeo Therapeutics (LXEO) Cash from Investing Activities (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Cash from Investing Activities data on file, last reported at $27.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 76.03% year-over-year to $27.5 million; the trailing twelve-month figure through Mar 2026 stood at -$78.4 million (changed 0.14% YoY), and the FY2025 full-year result was -$90.3 million, up 4.07% from the prior year.
• Cash from Investing Activities climbed to $27.5 million in Q1 2026, from -$101.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $35.0 million in Q3 2025 to a low of -$101.7 million in Q4 2025.
• A 5-year average of -$13.1 million and a median of -$95000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 128095.89% in 2024 and soared 42281.93% in 2025, its largest moves.
• Tracing LXEO's Cash from Investing Activities over 5 years: stood at -$107000.0 in 2022, then soared by 31.78% to -$73000.0 in 2023, then sank by 128095.89% to -$93.6 million in 2024, then dropped by 8.66% to -$101.7 million in 2025, then surged by 127.0% to $27.5 million in 2026.
• Business Quant data shows LXEO's Cash from Investing Activities at $27.5 million in Q1 2026, -$101.7 million in Q4 2025, and $35.0 million in Q3 2025.